TrialCephalalgia : an international journal of headache2019

Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine.

Messoud Ashina et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.